Drug · DIN 02282593
ACT RISPERIDONE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since June 26, 2018; first marketed July 5, 2006.
- Drug Identification Number (DIN)
- 02282593
- Company (DIN owner)
- Actavis Pharma CompanyToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 0.5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 5, 2015: NOC 17167Abbreviated New Drug Submission (ANDS) · Licensing agreement between two companies
- June 9, 2014: NOC 15705Abbreviated New Drug Submission (ANDS) · Manufacturer and product name change
- July 5, 2006: NOC 8112Abbreviated New Drug Submission (ANDS)
Other DINs named ACT RISPERIDONE
- DIN 02282585 · Cancelled Post Market
- DIN 02282607 · Cancelled Post Market
- DIN 02282615 · Cancelled Post Market
- DIN 02282623 · Cancelled Post Market
- DIN 02282631 · Cancelled Post Market